X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
CABA-201 is a 4-1BB-containing fully human CD19-CAR T cell investigational therapy. It is being evaluated in preclinical studies for the treatment of patients with systemic sclerosis.
Lead Product(s): CABA-201
Therapeutic Area: Immunology Product Name: CABA-201
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 20, 2024
Details:
CABA-201 is a 4-1BB-containing fully human CD19-CAR T cell investigational therapy, which is being evaluated in phase 1/2 clinical trials for the treatment of idiopathic inflammatory myopathies (IIM, or myositis).
Lead Product(s): CABA-201,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area: Musculoskeletal Product Name: CABA-201
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 01, 2024
Details:
CABA-201, a 4-1BB-containing fully human CD19-CAR T cell investigational therapy. It is being evaluated in preclinical studies for the treatment of dermatomyositis and systemic sclerosis.
Lead Product(s): CABA-201
Therapeutic Area: Immunology Product Name: CABA-201
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 08, 2024
Details:
CABA-201, a 4-1BB-containing fully human CD19-CAR T cell investigational therapy, has been allowed to proceed by the U.S. Food and Drug Administration (FDA) for a Phase 1/2 study in patients with generalized myasthenia gravis (gMG).
Lead Product(s): CABA-201
Therapeutic Area: Immunology Product Name: CABA-201
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 06, 2023
Details:
CABA-201 is a 4-1BB-containing fully human CD19-CAR T cell investigational therapy, has been cleared by the U.S. Food and Drug Administration for a Phase 1/2 study in patients with active idiopathic inflammatory myopathy (IIM, or myositis).
Lead Product(s): CABA-201
Therapeutic Area: Immunology Product Name: CABA-201
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 02, 2023
Details:
Under the agreement, WuXi ATU will serve as a cell processing manufacturing partner for the planned global clinical development of CABA-201, a 4-1BB-containing fully human CD19-CAR T, in systemic lupus erythematosus and idiopathic inflammatory myopathies, or myositis.
Lead Product(s): CABA-201
Therapeutic Area: Immunology Product Name: CABA-201
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Recipient: WuXi Advanced Therapies
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 22, 2023
Details:
The net proceedings will be used for expanded clinical development of CABA-201 in multiple indications, to advance manufacturing capabilities in preparation for late-stage trials and commercial readiness for CABA-201, and the ongoing development for its CAART programs.
Lead Product(s): CABA-201
Therapeutic Area: Immunology Product Name: CABA-201
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: TD Cowen
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering May 22, 2023
Details:
Cabaletta will use the net proceeds for expanded clinical development of CABA-201 in multiple indications, to advance manufacturing capabilities in preparation for late-stage trials and commercial readiness for CABA-201, and the ongoing development for its CAART programs.
Lead Product(s): CABA-201
Therapeutic Area: Immunology Product Name: CABA-201
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: TD Cowen
Deal Size: $87.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering May 17, 2023
Details:
CABA-201 is a 4-1BB-containing fully human CD19-CAR T cell investigational therapy, has been cleared by the U.S. Food and Drug Administration for a Phase 1/2 study in patients with active idiopathic inflammatory myopathy (IIM, or myositis).
Lead Product(s): CABA-201
Therapeutic Area: Immunology Product Name: CABA-201
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 16, 2023
Details:
CABA-201 is a 4-1BB-containing fully human CD19-CAR T cell investigational therapy, designed to deplete CD19-positive B cells and improve disease activity in patients with systemic lupus erythematosus and lupus nephritis.
Lead Product(s): CABA-201
Therapeutic Area: Immunology Product Name: CABA-201
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 01, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
